Market closed
Roivant Sciences/$ROIV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Roivant Sciences
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Ticker
$ROIV
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
908
Website
Roivant Sciences Metrics
BasicAdvanced
$8.3B
-
-$0.16
1.25
-
Price and volume
Market cap
$8.3B
Beta
1.25
52-week high
$12.57
52-week low
$8.73
Average daily volume
7.9M
Financial strength
Current ratio
37.912
Quick ratio
37.391
Long term debt to equity
1.634
Total debt to equity
1.812
Interest coverage (TTM)
-34.03%
Management effectiveness
Return on assets (TTM)
-11.29%
Return on equity (TTM)
-14.64%
Valuation
Price to revenue (TTM)
70.77
Price to book
1.61
Price to tangible book (TTM)
1.61
Price to free cash flow (TTM)
-11.13
Growth
Revenue change (TTM)
140.04%
Earnings per share change (TTM)
-102.80%
3-year revenue growth (CAGR)
26.05%
3-year earnings per share growth (CAGR)
-54.55%
What the Analysts think about Roivant Sciences
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Roivant Sciences stock.
Roivant Sciences Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Roivant Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Roivant Sciences News
AllArticlesVideos
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Seeking Alpha·1 week ago
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
GlobeNewsWire·2 weeks ago
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Roivant Sciences stock?
Roivant Sciences (ROIV) has a market cap of $8.3B as of May 03, 2025.
What is the P/E ratio for Roivant Sciences stock?
The price to earnings (P/E) ratio for Roivant Sciences (ROIV) stock is 0 as of May 03, 2025.
Does Roivant Sciences stock pay dividends?
No, Roivant Sciences (ROIV) stock does not pay dividends to its shareholders as of May 03, 2025.
When is the next Roivant Sciences dividend payment date?
Roivant Sciences (ROIV) stock does not pay dividends to its shareholders.
What is the beta indicator for Roivant Sciences?
Roivant Sciences (ROIV) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.